Boutique Biotech speaks with Affimed management at the Leerink Healthcare Conference
And updates on Medicenna's ongoing Phase 1/2 study of MDNA11
The XBI biotech index was starting to see some consolidation during February in the low-mid $90s. However, that was interrupted by the ongoing tensions between Russia/Ukraine. Biotech investors are still not seeing the reverse in sentiment that is needed for comfort to jump back into names. For the time being, we are waiting on the sidelines. Holding ex…